Julie Clauss

Julie Clauss is a highly experienced business leader currently serving as a Strategic Advisory Board Member at Odyssey Therapeutics.1 Her professional background includes:

Career Highlights

• Founder & Board Member at Aptabridge Therapeutics since September 20221
• Board Member at French Tech Boston since January 20211
• Vice President Gene Therapy Platform Lead at Ultragenyx Pharmaceutical Inc. from August 2021 to September 20221
• Vice President, Head of R&D Operations at IPSEN BIOSCIENCE, INC. from 2018 to 20201

Education

Julie holds an MIT Sloan Fellows MBA from the MIT Sloan School of Management, which she completed in 2021.1

Expertise

Julie Clauss has demonstrated excellent capabilities in:

• Defining business unit vision and strategy
• Managing global R&D operations
• Implementing critical R&D projects and initiatives
• Leading large teams and managing substantial budgets
• Driving integrated planning cultures within R&D organizations

Location

She is based in Cambridge, Massachusetts, United States.1

It's worth noting that while Julie Clauss has a significant role at Odyssey Therapeutics, her current LinkedIn profile does not specifically list her as Chief Operating Officer. Her most recent position related to Odyssey Therapeutics is listed as Strategic Advisory Board Member.1